Nature Communications · 2017 · 81 citations · 32 references
MedicineMolecular BiologyOncologyMolecular OncologySignal TransductionTranscriptional RegulationCancer Cell SignalingCell Signaling NetworksOncogenic Signaling PathwaysSignal Transduction In CancerTranscription Factor OncogenesTumor Suppressor GenesAdaptive ResistanceBraf V600 MutationsCancer Signaling PathwaysErk SignalingExtracellular Signal-regulated Kinase PathwayExtracellular Signal-regulated Kinase SignalingPhosphorylation-dependent RegulationRaf Signaling
In human mutant BRAF melanoma cells, the stemness transcription factor FOXD3 is rapidly induced by inhibition of ERK1/2 signaling and mediates adaptive resistance to RAF inhibitors. However, the mechanism underlying ERK signaling control of FOXD3 expression remains unknown. Here we show that SOX10 is both necessary and sufficient for RAF inhibitor-induced expression of FOXD3 in mutant BRAF melanoma cells. SOX10 activates the transcription of FOXD3 by binding to a regulatory element in FOXD3 promoter. Phosphorylation of SOX10 by ERK inhibits its transcription activity toward multiple target genes by interfering with the sumoylation of SOX10 at K55, which is essential for its transcription activity. Finally, depletion of SOX10 sensitizes mutant BRAF melanoma cells to RAF inhibitors in vitro and in vivo. Thus, our work discovers a novel phosphorylation-dependent regulatory mechanism of SOX10 transcription activity and completes an ERK1/2/SOX10/FOXD3/ERBB3 axis that mediates adaptive resistance to RAF inhibitors in mutant BRAF melanoma cells.
32
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty, Igor Puzanov, Kevin B. Kim et al. · New England Journal of Medicine · 2010 · 3.5K citations
Medicine, Oncology, Pharmacology +17
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty, J. Infante, Adil Daud et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text
Medicine, Oncology, Pharmacology +16
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text
Medicine, Oncology, Pharmacology +16
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman, Teppei Morikawa, Kevin Shee et al. · Nature · 2012 · 1.7K citations · Full text
Medicine, Cancer Biology, Oncology +15